Exemestane in the prevention setting
Cet article passe en revue les études concernant l'utilisation de l'exémestane dans la chimioprévention du cancer du sein
Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.
http://tam.sagepub.com/content/early/2012/02/21/1758834012438214.abstract